Tango Therapeutics, Inc. (TNGX)
Health Care ยท Pharmaceutical Preparations
Tango Therapeutics, Inc. (TNGX) is listed on Nasdaq, where its shares have traded since August 11, 2021. SentiSense covers Tango Therapeutics, Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations. Malte Peters is its chief executive officer. The company reports 137 employees, and its corporate website is www.tangotx.com.
About Tango Therapeutics, Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
Latest reported results
Tango Therapeutics Inc. reported revenue of $0.00 for Q2 FY2026, down 100.0% from the same period a year earlier.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 237 institutions reported holding TNGX, with 213.7 million shares worth $6.6 billion in aggregate. The largest reported holders were Rtw Investments, BlackRock and FMR. Of the 5 largest reported holders, 4 added shares and 1 held its position unchanged during the quarter.
More on TNGX
- TNGX sentiment: whether news and social coverage of Tango Therapeutics, Inc. leans bullish or bearish, and the stories driving it.
- TNGX ownership: all 237 reporting institutions, plus insider and congressional trades.
- TNGX financials: revenue, net income, operating margin and free cash flow through Q2 FY2026.
SentiSense also tracks daily options readings for Tango Therapeutics, Inc.: IV rank, put/call percentile, 25-delta skew and open-interest walls.
Frequently asked questions
What does Tango Therapeutics, Inc. do?
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer.
What sector is TNGX in?
SentiSense classifies Tango Therapeutics, Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations.
Where does TNGX stock trade?
Tango Therapeutics, Inc. (TNGX) is listed on Nasdaq, where its shares have traded since August 11, 2021.
Who is the CEO of Tango Therapeutics, Inc.?
Malte Peters is the chief executive officer of Tango Therapeutics, Inc..